Pharmaceuticals News and Research

RSS

Sir James Black inventor of beta-blockers passes away

Sir James Black passed away on Monday after a long illness, he was 85. Sir James Black is credited as the inventor of the beta-blocker drugs in 1962. These are drugs which play an important role in the treatment of angina and heart attacks. They are regarded as one of the major medical breakthroughs of the 20th Century in Pharmacology. Born in Uddingston, Lanarkshire, Sir James Black studied medicine at St. Andrews University.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

WHO H1N1 vaccine shipments headed to more developing countries

The WHO on Friday announced "it had delivered the first doses of H1N1 [swine flu] vaccine to Cuba, and a dozen countries in Africa would receive millions of doses in coming weeks," Reuters reports.

23 Mar 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Can-Fite BioPharma Ltd, a biopharmaceutical company, traded on the TASE and developing anti- inflammatory and anti-cancer drugs, announced today the filing of a patent application, in conjunction with the United Stated National Institutes of Health (NIH), for the treatment of Uveitis with its A3 adenosine receptor ligands.

23 Mar 2010

Somaxon Pharmaceuticals to sell 4 million common stock shares

Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.

23 Mar 2010

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

Lupin Pharmaceuticals, Inc. announced today that it has received tentative approval for the Company's Abbreviated New Drug Application for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration.

23 Mar 2010

DSM Biomedical expands resources and operations in the U.S. and Europe

DSM Biomedical, a global leader in biomedical materials science, today announced the expansion of its resources and operations in the United States and Europe to support the growing demand for the company’s portfolio of innovative polyurethanes for chronically implanted medical devices in the regions.

23 Mar 2010

Cambrex announces acquisition of IEP GmbH

Cambrex Corporation announced it has acquired IEP GmbH, a privately held company that is a leader in the field of industrial biocatalysis. IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes.

23 Mar 2010

Fulcrum Ventures invests $1.25M in Path-Tec

Fulcrum Ventures announced today that they invested $1.25 million in Path-Tec, LLC. Founded in 2005, Path-Tec provides clinical, pharmaceutical and research labs with a turnkey solution for kit design, production, client supply management and patient specimen tracking.

22 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL. Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.

22 Mar 2010

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson’s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology.

22 Mar 2010

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

22 Mar 2010

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

OSI Pharmaceuticals, Inc. will fully redeem on April 21, 2010 all of its remaining outstanding 3.25% Convertible Senior Subordinated Notes due 2023 pursuant to the terms of the indenture under which the Notes were issued in September 2003. The aggregate principal amount currently outstanding of the Notes is $60,467,000. The CUSIP number for these Notes is 671040 AD 5.

22 Mar 2010

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Cancer Research Technology has announced an exclusive agreement with Cephalon, Inc., an international biotechnology company, to collaborate on the development of small molecule inhibitors. These molecules will target specific members of the 'protein kinase C' superfamily of cell signalling proteins - which have been shown to be associated with the development of cancer.

22 Mar 2010

Haemacure obtains authorization to sell assets to Angiotech Pharmaceuticals

Haemacure Corporation announces that it has obtained authorization from the Superior Court of the Province of Québec to sell its assets to Angiotech Pharmaceuticals, Inc., a secured creditor of Haemacure. The United States Bankruptcy Court previously authorized the sale to Angiotech of the assets of Haemacure's U.S. subsidiary.

22 Mar 2010

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a primary focus in oncology and hematology, and TopoTarget A/S, today announced that the first patient has been dosed in a National Cancer Institute -sponsored Phase 1/2 trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in the first line treatment of advanced or recurrent thymic malignancies.

22 Mar 2010

Dow Jones reports on side effects of Labopharm's once-daily version of Trazodone, stock falls by 5%

After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to switch from less expensive generic versions. Dow Jones found that when compared, the side effects of Labopharm's drug fare no better than the generic versions that dominate the market.

22 Mar 2010

Pharmaceuticals News and Research

Sir James Black inventor of beta-blockers passes away

ChemGenex shares falter as FDA requests more data on new leukemia drug

WHO H1N1 vaccine shipments headed to more developing countries

FDA approves APP Pharmaceuticals' Indomethacin for Injection

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Can-Fite BioPharma files patent application for treatment of Uveitis with A3 adenosine receptor ligands

Somaxon Pharmaceuticals to sell 4 million common stock shares

LPI's ANDA for Eszopiclone tablets receives tentative approval from USFDA

DSM Biomedical expands resources and operations in the U.S. and Europe

Cambrex announces acquisition of IEP GmbH

Fulcrum Ventures invests $1.25M in Path-Tec

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Patient dosing in CyDex Pharmaceuticals' Phase 2A clinical trial of CDX-353 initiated

Rexahn Pharmaceuticals forms Parkinson’s Disease SAB to develop strategy for Serdaxin

Decision Resources forecasts multiple myeloma drug market to more than double from $2.1B in 2008 to $5.3B in 2018

OSI Pharmaceuticals to redeem outstanding 3.25% Convertible Senior Subordinated Notes due 2023

CRT, Cephalon to collaborate on development of small molecule inhibitors against cancer

Haemacure obtains authorization to sell assets to Angiotech Pharmaceuticals

First patient dosed in NCI-sponsored Phase 1/2 trial of belinostat

Dow Jones reports on side effects of Labopharm's once-daily version of Trazodone, stock falls by 5%

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence